TTI Thiogenesis Therapeutics, Corp.

0.4124USD0.5900 CAD · TSXV-1.67%Mkt Cap: 28.86M USDP/E: —

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs t…

Key Statistics

Company
Market Cap28.86M USD
Enterprise Value23.78M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-5.19M USD
Revenue/Share—
Last Price0.4124 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA88410L1022
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B6.15
EPS (TTM)-0.08 USD
EPS (Forward)—
52W Range
0.307654% of range0.5033
52W High0.5033 USD
52W Low0.3076 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1292.89%
ROA-409.16%
ROIC—
ROCE-1287.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.22M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-10.39%
Net Debt-5.09M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio10.81
Quick Ratio10.69
Book Value/Sh0.07 USD
Cash/Share0.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.69.98M
Float55.42M
Insiders14.16%
Institutions0.00%
Short Interest
Short Ratio0.1d
Short % Out.0.00%
Shares Short2.29K
Short (prev mo.)7.24K
Technical
SMA 500.3862 (+6.8%)
SMA 2000.3835 (+7.6%)
Beta0.61
S&P 52W Chg12.08%
Avg Vol (30d)20.93K
Avg Vol (10d)8.19K
Technical Indicators
RSI (14)49.7
MACD0.0213
MACD Signal0.0273
MACD Hist.-0.0061
BB Upper0.4902 USD
BB Middle0.4241 USD
BB Lower0.3581 USD
BB Width31.15%
ATR (14)0.0174 USD
Vol Ratio (20d)0.40x

About Thiogenesis Therapeutics (CVE: TTI)

›

Thiogenesis Therapeutics (CVE: TTI) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.5900 CAD on 18 November 2026, down 20.3% over 52 weeks. Its 52-week range is 0.4400 CAD to 0.7200 CAD: the price is 18.1% below the high and 34.1% above the low.

Its market capitalisation is 41.29M CAD.

Thiogenesis Therapeutics reports an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 7.27M CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.